Outcome and evaluation of prognostic factors after pancreaticoduodenectomy for distal cholangiocarcinoma

Johannes Byrling, Roland Andersson, Agata Sasor, Gert Lindell, Daniel Ansari, Johan Nilsson, Bodil Andersson

Clinical Sciences Lund, Lund University and Skåne University Hospital, Sweden

Abstract

Background The aim of the present study was to examine the outcomes and prognostic factors after surgery with curative intent for distal cholangiocarcinoma during a modern timespan, in a Swedish tertiary referral center.

Methods All patients who underwent pancreaticoduodenectomy for distal cholangiocarcinoma between April 2008 and December 2015 were identified. Survival was estimated using the Kaplan-Meier analysis. Demographic, clinical, laboratory and histopathological data were evaluated for prognostic factors relating to mortality, using univariable and multivariable statistical analysis.

Results Fifty-four patients were included. The mean age was 68±8 years and 21 (39%) of the patients were female. Jaundice was present at diagnosis in 73% of the patients. There was no 90-day mortality. Complications graded as Clavien-Dindo ≥3 occurred in 10 (19%) of the patients. Twenty-eight (52%) received adjuvant therapy. Overall survival rates at 1, 3, and 5 years were 80%, 21%, and 9.2%, respectively. Median survival was 22.2 months. The presence of lymph node metastases was found to be the only independent predictor of survival (hazard ratio 2.88, 95% confidence interval 1.22-6.84; P=0.016). The total number of lymph node metastases, lymph node ratio or total number of resected nodes did not improve the prediction.

Conclusions We found that the recurrence rate was higher and the survival poorer after surgery for distal cholangiocarcinoma than has previously been reported. Lymph node status at the time of resection was the most important prognostic factor for survival in the current material.

Keywords Distal cholangiocarcinoma, survival, prognostic factor, lymph node metastasis

Introduction

Cholangiocarcinoma (CCA) is an epithelial cell malignancy arising along the biliary tree. The current classification, based on anatomical location, defines CCAs as either intrahepatic (iCCA) or extrahepatic (eCCA). eCCAs are then further distinguished as either perihilar (pCCA) or distal (dCCA) [1]. dCCA originates between the insertion of the cystic duct and up to but not including the ampulla of Vater [2,3]. CCA is a rare malignancy. The incidence of eCCA in western countries varies between 0.5-1.2 cases per 100,000 inhabitants [4]. However, the incidence is significantly higher in some Asian countries [5].

The overall survival of patients with CCA is low, with 5-year survival being less than 5% [6]. Neither radiotherapy nor chemotherapy represents an effective treatment option, and currently the only treatment with curative potential regardless of tumor location is surgery. However, surgery with curative intent is only possible in about one third of the patients [7]. The procedure of choice for dCCA is a pancreaticoduodenectomy (PD) [2]. The evidence for adjuvant treatment with chemotherapy or radiotherapy is inadequate, and current recommendations are primarily based on non-randomized studies [8]. The rate of recurrence after surgery is high. A meta-analysis of surgical outcomes after resection for dCCA, including 3258 patients operated between 1973 and 2013, reported that the 5-year survival for dCCA was between
13-54% [9]. It was shown that R1 resection, lymph node metastasis (LNM), perineural invasion, lymphatic invasion, vascular invasion, pancreatic invasion, and pathological tumor stage ≥T3 were associated with shorter survival [9].

The aim of the present study was to examine the surgical outcomes and prognostic factors for dCCA, during a modern timespan, in a Swedish tertiary referral center [10].

Patients and methods

The study was approved by the Regional Human Ethics Committee in Lund Sweden.

Patient population

All consecutive patients undergoing resection for dCCA at the Department of Surgery, Skåne University Hospital, Lund and Malmö, between April 2008 and December 2015, were identified from hospital records, aided by a computer search (International Classification of Disease-10, surgical classification code JLC40). The medical records were reviewed retrospectively. Inclusion criteria were PD with a histopathologically confirmed dCCA. During the study period, Skåne University Hospital served as the referral center for all periampullary malignancies in the south of Sweden (population approximately 1.7 million).

Preoperative biliary drainage (PBD)

PBD was performed at the patients' local hospital in accordance to local guidelines. At our center it is not performed routinely; however, a majority of patients receive PBD prior to surgery. Endoscopic biliary drainage is considered the primary alternative and percutaneous biliary drainage as a secondary alternative.

Operative procedure

PD was performed as a partial pancreatectomy with classic resection, including limited distal gastrectomy and standard lymphadenectomy. The reconstruction was performed with a pancreaticogastrostomy, and with gastroenterostomy and hepaticojejunostomy performed on the same jejunal loop [10].

Follow up

Patients were seen one month after surgery at the outpatient clinic with a clinical examination, and information about the histopathological diagnosis and further treatment options. Adjuvant therapy was administered at the patients' local hospital. Follow up was performed every 6 months for two years and then annually up to five years postoperatively, and included computed tomography and liver enzymes, as well as carbohydrate antigen 19-9 (CA 19-9). Patient follow-up data were acquired through patient records that were reviewed retrospectively. Adjuvant chemotherapy was recorded, as well as the time and location of eventual recurrences. Recurrences and survival status were recorded on the 18th of February 2016. Survival status was determined using the Patient Administrative Support in Skåne (PASIS) database.

Variables included in the survival analysis

Variables that were considered appropriate for outcome analysis included general clinical information at the time of operation (age, sex, body mass index, history of diabetes, history of smoking, type of preoperative biliary drainage, preoperative cholangitis), and preoperative blood samples (hemoglobin, thrombocytes, leukocytes, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, albumin, CA 19-9, C-reactive protein, and total bilirubin). Perioperative factors (operative time, estimated blood loss, blood transfusions during surgery and up to 30 days postoperatively, vascular resection, American Society of Anesthesiologists [ASA] score) [11] and postoperative complications within 30 days of surgery or during the same hospitalization period as the operation) were recorded. For histopathological evaluation, all tumor specimens were retrieved and reexamined in order to obtain a standardized assessment. All specimens were reassessed in accordance with the WHO classification of tumors of the digestive system, 4th edition [12]. The reassessments were made by an experienced gastrointestinal pathologist (AS). Pathological evaluation included tumor size, grading based on the predominant morphological pattern (low/moderate/high differentiation), presence of LNM, total number of lymph nodes examined, lymph node ratio (LNR), perineural invasion, microvascular invasion, lymphatic invasion, pancreatic invasion and peripancreatic fat invasion. In three patients we were unable to retrieve material for reevaluation and available data were collected from the initial pathological records. Assessment of radical resection was based on the initial pathology records, as available material did not allow for reassessment of the resection margins.

Study definitions

The level of complications was graded according to the Clavien-Dindo system [13]. Post-pancreatectomy hemorrhage, and delayed gastric emptying were graded A-C in accordance with the International Study Group of Pancreatic Surgery (ISGPS) definitions [14,15]. Postoperative pancreatic fistula was graded B-C in accordance with the updated ISGPS criteria [16]. Tumor staging was based on the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 7th edition [3]. The definition for R0 resection was ≥1 mm from cancer growth. The CA 19-9 was dichotomized at 35 kE/L, which is the upper limit of the normal reference interval [17]. LNR is the number of positive nodes/total number of resected
nodes. We choose to employ a LNR cutoff of 0.17, as has been reported previously [18].

Statistical analysis

Values of continuous variables are given as mean ± standard deviation or median and interquartile range. For categorical values, absolute numbers and the distribution in percentages on available data are given. The Kaplan-Meier analysis was used to estimate long-term survival. Differences in survival were analyzed using a univariable Cox proportional hazards regression (CPH) model. Variables with a P-value <0.2 from the univariable analyses were included in the multivariable analysis. A CPH model, with stepwise backward selection (removal limits of P<0.100), was used to identify independent predictors of survival. To determine the optimal measurement of LNM (presence/absence of LNM, total number of LNM, total number of resected lymph nodes or cutoff LNR of 0.17) for discriminating survival, χ² scores, calculated using the Cox proportional hazards model, were compared. The maximum χ² score was taken as the optimal model. P-values <0.05 were considered significant. Hazard ratios (HRs) are presented with 95% confidence intervals (CI). Statistical analysis was performed with Stata MP statistical package version 14.2, 2016 (Stata Corporation, College Station, Texas, USA).

Results

A total of 54 patients, 33 men and 21 women, fulfilled the inclusion criteria. The patients were between 53 and 85 years old with a mean of 68±7.7 years at the time of surgery. Most patients had ASA score II 27 (50%) or III 22 (41%) preoperatively. The following symptoms were present upon presentation: Jaundice 39 (72%), abdominal pain 19 (35%), weight loss 10 (19%), nausea/vomiting 6 (11%), while no patient had fever upon presentation (Table 1).

The most common postoperative complications were delayed gastric emptying, with 9 (17%) having grade B or C, wound infection, deep abdominal infection, postoperative pancreatic fistula, and cholangitis (Table 2). According to the Clavien-Dindo classification, 17 (31%) had a grade I complication, 20 (37%) grade II, 4 (7.2%) grade IIIa, 1 (1.9%) grade IIIb, 3 (5.6%) grade IVa and 1 (1.9%) grade IVb (Table 2). Reoperation was performed in 1 patient because of ileus. One patient with abdominal bleeding underwent angiographic coiling of the superior mesenteric artery. There was no 90-day mortality. The average hospital stay was 16.5 days.

The histopathological examination revealed LNM in 39 (72%) patients. The tumor was classified as poorly differentiated in 43 (80%) samples. Thirty-four (63%) patients had R1-resections. When staged in accordance with AJCC 7th edition, 15 tumors (28%) were stage Ia, 38 (70%) were stage IIb and 1 (1.9%) was stage III (Table 3).

Table 1 Preoperative clinicopathological data for patients with distal cholangiocarcinoma

<table>
<thead>
<tr>
<th>Variable</th>
<th>N</th>
<th>n (%)</th>
<th>mean±SD or median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical data</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>54</td>
<td>68±7.7</td>
<td></td>
</tr>
<tr>
<td>Female sex</td>
<td>54</td>
<td>21 (39%)</td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>54</td>
<td>25±3.5</td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>54</td>
<td>15 (28%)</td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td>50</td>
<td>20 (40%)</td>
<td></td>
</tr>
<tr>
<td>PBD</td>
<td>54</td>
<td>53 (98%)</td>
<td></td>
</tr>
<tr>
<td>ERCP-guided drain</td>
<td>54</td>
<td>48 (89%)</td>
<td></td>
</tr>
<tr>
<td>PTC-guided drain</td>
<td>54</td>
<td>5 (9%)</td>
<td></td>
</tr>
<tr>
<td>Preoperative cholangitis</td>
<td>54</td>
<td>14 (26%)</td>
<td></td>
</tr>
<tr>
<td><strong>Symptoms at presentation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jaundice</td>
<td>54</td>
<td>39 (72%)</td>
<td></td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>54</td>
<td>19 (35%)</td>
<td></td>
</tr>
<tr>
<td>Weight loss</td>
<td>54</td>
<td>10 (19%)</td>
<td></td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>54</td>
<td>6 (11%)</td>
<td></td>
</tr>
<tr>
<td><strong>Preoperative laboratory status</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hb (g/L)</td>
<td>54</td>
<td>128 (120-138)</td>
<td></td>
</tr>
<tr>
<td>Leukocyte count (cells ×10⁹/L)</td>
<td>54</td>
<td>7.8 (6-9)</td>
<td></td>
</tr>
<tr>
<td>Thrombocyte count (cells ×10⁹/L)</td>
<td>54</td>
<td>270 (230-341)</td>
<td></td>
</tr>
<tr>
<td>ASAT (µkat/L)</td>
<td>54</td>
<td>0.5 (0.4-1.0)</td>
<td></td>
</tr>
<tr>
<td>ALAT (µkat/L)</td>
<td>54</td>
<td>0.8 (0.5-1.2)</td>
<td></td>
</tr>
<tr>
<td>ALP (µkat/L)</td>
<td>54</td>
<td>2.7 (1.7-4.7)</td>
<td></td>
</tr>
<tr>
<td>Albumin (g/L)</td>
<td>44</td>
<td>34 (30-38)</td>
<td></td>
</tr>
<tr>
<td>Bilirubin (µmol/L)</td>
<td>54</td>
<td>18 (9-34)</td>
<td></td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>50</td>
<td>5.8 (2-16)</td>
<td></td>
</tr>
<tr>
<td>CA 19-9 (KE/L)</td>
<td>50</td>
<td>142 (54-353)</td>
<td></td>
</tr>
</tbody>
</table>

N number of non-missing values. Qualitative data are expressed as n (%) and quantitative data as mean±SD or median (IQR)

ALAT, alanine aminotransferase; ALP, alkaline phosphatase; ASAT, aspartate aminotransferase; BMI, body mass index; CA 19-9, carbohydrate antigen 19-9; CRP, C-reactive protein; ERCP, endoscopic retrograde cholangiopancreatography; Hb, hemoglobin; IQR, interquartile range; PBD, preoperative biliary drainage; PTC, percutaneous transhepatic cholangiography

capcitabine with concomitant radiotherapy, 1 patient capcitabine as monotherapy and 1 patient 5-fluorouracil/leucovorin as monotherapy. No difference in survival was seen between patients who received adjuvant therapy and those who did not.

Overall survival rates at 1, 3, and 5 years were 80% (95% CI 66-89%), 21% (95% CI 9.5-35%) and 9.2% (95% CI 2.0-23%), respectively (Fig. 1). Median survival was 22.2 months. After one and three years, recurrence had occurred in 55% and 82% of patients, respectively. The median time to recurrence was 13 months. The most common recurrence location was liver.
metastasis in 17 (31%) patients, followed by local recurrence in 13 (24%) patients and lymph node recurrence in 5 (9.3%) patients (Table 3).

The presence of LNM and their total number were found to be significantly associated with worse overall survival in the univariable analysis, but no significant association was found for the total number of resected nodes (P=0.734) or LNR (P=0.148). The median survival was 28 months in the lymph node-negative and 21 months in the lymph node-positive group. At 3 years, 47% of patients were estimated to be alive in the lymph node-negative group and 11% in the lymph node-positive group (Table 4).

In the multivariable analysis, using a stepwise approach, the $\chi^2$ score was calculated for three prediction models: presence/
absence of LNM, total number of LNM, and LNR cutoff 0.17; the models included the other covariates presented in Table 4. The presence/absence of LNM was identified as the only independent risk factor for worse survival, HR 2.88 (95% CI 1.22-6.84; P=0.016), with the highest CPH χ² score. Survival after PD for dCCA with and without LNM is presented in Fig. 2.

Discussion

The only possible cure for patients with dCCA is surgical resection, but the prognosis is dismal. We aimed to identify risk factors and investigate the outcomes after surgery for dCCA, during a modern time period in a tertiary western center. Previous studies were mainly of Asian origin and data were collected over longer time spans, during which changes in diagnostic and operative procedures may have occurred.

In the present study, a high risk for recurrence after surgery was evident. The median survival was 22.2 months, with an estimated 5-year survival of 9%. This is a poor outcome compared to previous studies, where 5-year survival ranging between 13-54% has been reported [9]. Although the results are heterogeneous, several recent larger Asian studies report 5-year survival rates of over 40% after resection for dCCA [17-19]. In western reports with patient inclusion between 1987 and 2016, the majority of studies report a 5-year survival after surgical resection for dCCA ranging between 18-29% [20-27], with a few studies reporting even better survival [28,29]. The median survival in our study, although still in the lower ranges, is consistent with some previous reports [21,23,25]. Differences in incidence, risk factors and genetic factors that are known to differ between western countries and Asian countries [5,30] could impact the outcome after resection for dCCA. In addition, differences in patient selection could impact differences in outcome, both between and within countries. When comparing our results with those of previous studies, we noted more advanced tumors with a high frequency of risk factors for poor outcome, such as the presence of LNM 72% versus 22-68% [31,32], perineural invasion 85% versus 33-85% [27,33], lymphatic invasion 77% versus 11-81% [27,33], vascular invasion 65% versus 7-74% [34,35], and R1-resection 63% versus 4-72% [36,37]. These discrepancies could partly be attributed to differences in the histopathological examination of tumor specimens, as well as the definition of R1-resection after PD [38,39]. Recently, it has been shown that survival after PD for dCCA and pancreatic ductal adenocarcinoma, to which a worse prognosis has traditionally been attributed, may be similar when matched for variables affecting outcome [20].

We confirmed lymph node status as an important independent risk factor for poor survival in dCCA. Based on

### Table 4

Univariable analysis of relevant clinicopathological risk factors after resection for distal cholangiocarcinoma. Variables with P≤0.2 that were selected for multivariable analysis are presented

<table>
<thead>
<tr>
<th>Variables</th>
<th>Hazard ratio</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASA-score ≥3</td>
<td>1.84</td>
<td>0.94-3.63</td>
<td>0.077</td>
</tr>
<tr>
<td>CRP</td>
<td>0.98</td>
<td>0.97-1.01</td>
<td>0.159</td>
</tr>
<tr>
<td>CA 19-9 ≥35</td>
<td>2.34</td>
<td>0.90-6.10</td>
<td>0.081</td>
</tr>
<tr>
<td>Lymph node metastasis (yes/no)</td>
<td>2.88</td>
<td>1.22-6.84</td>
<td>0.016</td>
</tr>
<tr>
<td>Lymph node ratio ≥0.17</td>
<td>1.67</td>
<td>0.83-3.35</td>
<td>0.148</td>
</tr>
<tr>
<td>Number of lymph node metastases</td>
<td>1.08</td>
<td>1.01-1.15</td>
<td>0.017</td>
</tr>
<tr>
<td>Lymph vessel invasion</td>
<td>1.93</td>
<td>0.84-4.45</td>
<td>0.123</td>
</tr>
<tr>
<td>Perineural invasion</td>
<td>2.30</td>
<td>0.70-7.55</td>
<td>0.168</td>
</tr>
<tr>
<td>Adipose tissue invasion</td>
<td>2.54</td>
<td>0.88-7.33</td>
<td>0.086</td>
</tr>
<tr>
<td>R1-resection</td>
<td>1.61</td>
<td>0.79-3.27</td>
<td>0.186</td>
</tr>
</tbody>
</table>

Differences in survival were analyzed using a univariable Cox-regression model

ASA, American society of anesthesiologists; CA 19-9, carbohydrate antigen 19-9; CRP, C-reactive protein; R1-resection, non-radical resection.
### Summary Box

**What is already known:**

- Distal cholangiocarcinoma is a rare malignancy originating between the insertion of the cystic duct and up to but not including the ampulla of Vater.
- The only treatment with curative potential is surgery; however, the rate of recurrence is high.
- R1 resection, lymph node metastasis, perineural invasion, lymphatic invasion, vascular invasion, pancreatic invasion and pathological tumor stage ≥T3 have been associated with shorter survival.

**What the new findings are:**

- We found a 5-year survival of 9% and a median survival of 22 months after pancreaticoduodenectomy for distal cholangiocarcinoma, which are lower than those reported in most previous studies.
- We found the presence of lymph node metastasis to be the only independent risk factor for poor survival.
- The total number of lymph node metastases, lymph node ratio and the total number of resected nodes did not improve the prediction.

The strength of the current study is the strict inclusion criteria, where only true dCCAs were included, while pCCAs as well as pancreatic and ampullary tumors were excluded. Furthermore, all the surgical specimens were reevaluated systematically by an experienced gastrointestinal pathologist in order to guarantee the quality. Moreover, the extensive follow up was complete, with no missing cases, and the study duration was limited in order to avoid the impact of changes in clinical treatment, including chemotherapy, over time.

The main limitation of this study is its retrospective design and the low number of patients included. The low number of patients at risk after 5 years makes the estimation of the 5-year survival uncertain.

In conclusion, we found dCCAs to be an aggressive malignancy, with a higher rate of recurrence and mortality after surgical resection compared to previous publications and a survival more similar to pancreatic ductal adenocarcinoma. The presence of LNM is the most important prognostic factor for survival, but measuring the number of LNM, the number of resected nodes, and the LNR does not improve the prediction.

---

**Acknowledgment**

We would like to express our gratitude to senior consultant Robert Szepesvari for assistance in retrieving follow-up data.

### References

Prognostic factors for distal cholangiocarcinoma


